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Abstract
Background: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is characterised by severe prolonged
fatigue, and decreases in cognition and other physiological functions, resulting in severe loss of quality of life,
difficult clinical management and high costs to the health care system. To date there is no proven
pathomechanism to satisfactorily explain this disorder. Studies have identified abnormalities in immune function
but these data are inconsistent. We investigated the profile of markers of immune function (including novel
markers) in CFS/ME patients.
Methods: We included 95 CFS/ME patients and 50 healthy controls. All participants were assessed on natural killer
(NK) and CD8
+T cell cytotoxic activities, Th1 and Th2 cytokine profile of CD4
+T cells, expression of vasoactive
intestinal peptide receptor 2 (VPACR2), levels of NK phenotypes (CD56
bright and CD56
dim) and regulatory T cells
expressing FoxP3 transcription factor.
Results: Compared to healthy individuals, CFS/ME patients displayed significant increases in IL-10, IFN-g, TNF-a,
CD4
+CD25
+ T cells, FoxP3 and VPACR2 expression. Cytotoxic activity of NK and CD8
+T cells and NK phenotypes, in
particular the CD56
bright NK cells were significantly decreased in CFS/ME patients. Additionally granzyme A and
granzyme K expression were reduced while expression levels of perforin were significantly increased in the CFS/ME
population relative to the control population. These data suggest significant dysregulation of the immune system
in CFS/ME patients.
Conclusions: Our study found immunological abnormalities which may serve as biomarkers in CFS/ME patients
with potential for an application as a diagnostic tool.
Background
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
(CFS/ME) remains a medically unexplained disorder
despite numerous scientific investigations undertaken
worldwide. The current worldwide prevalence rate of
CFS/ME is estimated to be about 0.5% [1] with a higher
prevalence in females compared to males, at a ratio of up
to 6:1 [2]. The annual cost for treatment and manage-
ment of CFS/ME in the USA is estimated to be US$319
million with a direct cost of US$7,406 per patient [3].
Generally, patients with CFS/ME experience severe
fatigue, neuropsychological impairments, and other asso-
ciated flu-like symptoms before a firm diagnosis of CFS/
ME is made [4]. CFS/ME has been observed to persist
for more than six months where symptoms may
decrease, remain stable or worsen [3]. The current diag-
nostic strategy for health professionals is based on case
definition, although this is not the most ideal method as
it permits misdiagnosis. CFS/ME may share homology
with certain disorders classified as fatigue related disor-
ders where individuals experience fatigue and one or
more of CFS/ME related symptoms. Further, there are
no biomarkers available to affirm diagnosis thus compli-
cating treatment.
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between infections, neurological and neuroimmune
dysfunctions and clinical manifestations of CFS/ME
[5-10]. Immunity has been widely investigated in
patients with CFS/ME but the results of these studies
are inconsistent, reporting different lymphocyte cell
numbers and cytokine distributions in patients with
CFS/ME. Nonetheless, findings on immunoglobulins,
complement markers and activation molecules in CFS/
ME, may demonstrate an underlying infringement in
immune function [8,11,12]. Decreased function of lym-
phocytes, in particular Natural Killer (NK) cell cyto-
toxic activity in CFS/ME patients compared to healthy
controls, seems to be a consistent finding [13-16]. The
functional capacity of other immune cells, such as T
cells, and the contribution of other molecules in the
pathophysiological mechanism of CFS/ME, remains to
be determined. In particular, the role of subsets of
CD4
+Ta n dt h eC D 8
+T cell populations has not been
fully studied in CFS/ME. Importantly, recent data on
cytokine distribution in CFS/ME patients point
t o w a r d sa ni n c r e a s ei np r o -inflammatory cytokines
suggesting the presence of an underlying viral preva-
lence in these patients [17,18] and this can be detri-
mental to the immune inflammatory processes.
It is widely known that neuropeptides regulate immu-
nity. Relevant among these are vasoactive neuropeptides
(VNs), specifically vasoactive intestinal peptide (VIP)
and pituitary adenylate cyclase-activating polypeptide
(PACAP). They regulate and suppress pro-inflammatory
immune processes via the PKA/cAMP pathway [19].
Their role in CFS/ME remains unknown although there
are suggestions that they may be implicated in CD4
+T
cell related activities such as cytokine secretion and
FoxP3 expression [20].
Immune cell numbers may not necessarily be indicative
of diseased states, as stated previously these have been
shown to be inconsistent in CFS/ME. However, the func-
tional capacity of these cells during disease progression
may provide a better understanding of the mechanism
associated with unexplained disorders such as CFS/ME.
Alternatively, this may help in identifying specific immune
parameters that can be used as diagnostic markers for
CFS/ME. The present study thus explores immunological
abnormalities that may serve as biomarkers for diagnosing
CFS/ME. Additionally, this is the first study to examine
t h er o l eo fV N s ,V I Pa n dP A C A P ,a n dF o x P 3e x p r e s s i o n
in CFS/ME.
Methods
The project having been reviewed under an Expedited
Review Procedure was granted approval to proceed by
the Bond University Human Research Ethics Committee
(BUHREC). All participants in this present study signed
an informed consent approved by the Bond University
Human Research Ethics Committee (BUHREC).
Participants
All participants, both CFS/ME and non-fatigued controls
were recruited from Queensland and New South Wales
states in Australia through the CFS/ME support groups,
newspaper and email advertisements into a prospective
study as cases (CFS/ME patients) or non-fatigued con-
trols (healthy volunteers). Participants were eligible if
they were between 25 and 65 years old. Prior to inclusion
all participants completed a consent form and a Chronic
Fatigue Syndrome questionnaire based on the Centre for
Disease Prevention and Control case definition (CDC
1994) [4]. Participants previously diagnosed with autoim-
mune disorders, psychosis, epilepsy, heart disease, or who
were pregnant or breastfeeding were excluded from the
study (Figure 1).
Sample Preparation and Routine Measurements
A volume of 25 ml of blood was collected from the ante-
cubital vein of participants into lithium heparinised and
EDTA collection tubes between 9 am and 11 am. Blood
samples were analysed within 12 hours of collection.
Routine blood cell counts for red blood cells, lympho-
cytes, granulocytes and monocytes were performed using
an automated cell counter (ACT Differential Analyzer,
Beckman Coulter, Miami, FL).
Assessment of NK Cytotoxic Activity
NK cells were isolated from whole blood samples using
Ficoll-Hypaque (GE Healthcare Life Sciences; Milan, Italy)
density gradient centrifugation. NK lymphocyte cytotoxic
activity was performed as previously described [21].
Briefly, isolated cells were labelled with 0.4% PKH-26
( S i g m a ,S tL o u i s ,M O ) .N Kc e l l sw e r ei n c u b a t e dw i t h
K562 cells at an effector to target ratio of 25: 1, for 4
hours at 37°C in 95% air, 5% CO2. Apoptosis of the
tumour cells was measured via FACS-Calibur flow cyto-
metry using the Cell Quest Software (Becton Dickinson
(BD), San Diego, CA), using Annexin V-FITC and 7-AAD
reagent (BD Pharmingen, San Diego, CA). Percent lysis of
K562 cells was calculated as previously described [21].
Assessment of CD8
+T lymphocyte Cytotoxic Activity
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood samples using Ficoll-Hypaque
(GE Healthcare Life Sciences; Milan, Italy) density gradi-
ent centrifugation. CD8
+T lymphocytes were preferen-
tially isolated from PMBCs using CD8
+Tc e l li s o l a t i o n
kit (Miltenyi Biotec GmbH; Bergisch-Gladbach, Ger-
many) according to the manufacturer’si n s t r u c t i o n s .
Briefly, cells were stained with a CD8
+T cell biotin-anti-
body cocktail, incubated for 10 minutes and then
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+T cell micorbead cocktail for 15 min-
utes. Cells were then passed through separation columns
where cells of interest were collected for further analy-
sis. Cytolysis was performed as previously described
using P815 cells as the target cells [22]. In brief, P815
cells were stained with 0.4% PKH-26 and activated using
anti-CD3 (BD Bioscience, San Diego, CA). The target
cells were then incubated with CD8
+T cells at an effec-
tor to target ratio of 25: 1, for 4 hours at 37°C in 95%
air, 5% CO2. Annexin V-FITC flow cytometry apoptosis
detection was used in assessing cell death of the tumour
cells. Percent lysis of P815 cells was calculated as pre-
viously described [22].
Gene Expression in NK and CD8
+T cells
Isolation of NK and CD8
+T cells was done via MACS
separation (Miltenyi Biotec GmbH; Bergisch-Gladbach,
Germany) as specified by the manufacturer. Purity was
determined on the flow cytometer using the Cell Quest
software. Isolated NK cells were coated with PE-
CD56CD16 and FITC-CD3 (BD Pharningen, San Diego,
CA) monoclonal antibodies to determine the purity of
NK cells. To establish the purity of CD8
+T cells, isolated
CD8
+T cells were stained and incubated with PE-CD8
and FITC-CD3 monoclonal antibodies (BD Pharmingen,
San Diego, CA). Cells were fast frozen in liquid nitrogen
and kept in negative 80 degrees freezing conditions for
further assessment. Total RNA extractions were per-
formed using the RNeasy Mini Kit (Qiagen, Valencia,
CA) and quantified on the NanoDrop 3300 (Thermo
Scientific, Wilmington, DE). RNA was synthesised in to
cDNA using the SuperScript™ III First-Strand synthesis
SuperMix for qRT-PCR (Invitrogen, Carlsbad, CA) as
specified by the manufacturer and stored at negative 20°
C for later analysis. RT-qPCR was performed using IQ
SYBR Green Super Mix (Bio-Rad, Hercules, CA) with
GAPDH as the housekeeping gene. Expression levels of
granzyme A, granzyme K, perforin and interferon (IFN)-
g (GZMA, GZMK, PRF1 and IFN-G) genes were col-
lected and quantified using the iQCycler (Bio-Rad, Her-
cules, CA).
Quantification of NK Phenotypes
Distribution of NK cell phenotypes was assessed as pre-
viously described [23]. NK lymphocytes were isolated
from whole blood via negative selection using Rosette-
Sep Human Natural Killer Cell Enrichment Cocktail
(StemCell Technologies, Vancouver, BC) and were
labelled with CD56-FITC and CD16-PE monoclonal
antibodies (BD Pharmingen, San Jose, CA).
Figure 1 Selection Process for Experimental Groups. Participants for the present project were grouped into CFS/ME, or non-fatigued control
groups based on the CDC 1994 case definition symptom criteria. Participants, that is, both CFS/ME and non-fatigued controls, were comprised of both
male and females selected using advertisements and through the CFS/ME support groups. Non-fatigued controls were randomly selected from the
general population using newspaper and email advertisements. The above flow chart illustrates the process used to generate the final research
population.
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Whole blood samples (10 mL) diluted with 1x PBS were
layered over Ficoll-Hypaque for isolation of peripheral
blood mononuclear cells. Cells were stimulated with or
without 1 μg of Lipopolysaccharide (Invitrogen, Carlsbad,
CA) and cultured for 48 hours. Cells were stained with
vasoactive intestinal peptide receptor 2 (Sigma, St Louis,
MO), FITC-IgG (Sigma, St Louis, MO) and CD4-PE anti-
mouse monoclonal antibodies and analysed on the flow
cytometer with settings for detecting monocytes and lym-
phocytes expressing the VPACR2 [24]. Percentage of
cells expressing both CD4-PE and VIP2-FITC were
recorded from these populations to determine the levels
of VPACR2 expressed on these cells. In the lymphocyte
gate specific reference was made for CD4
+T cells.
Cytokine Determination
Isolated PBMCs were mitogenically stimulated with 1 μg
of phytohemagluttinin and cultured at a concentration
of 1 × 10
6 cells/mL for 72 hours. Following incubation,
supernatants were removed and stored at -80°C for later
assessment. T helper (Th)1, Th2 and Th17 cytokine
expressions were investigated using the cytometric bead
array kit (BD Pharmingen, San Diego, CA) [25] for
determining levels of interleukin (IL)-2, IL-4, IL-6, IL-
10, tumour necrosis factor (TNF)-a,I N F - g and IL-17A.
The cytokines selected for this study although not con-
clusive, enough were selected to ascertain the Th1/Th2/
Th17 mechanisms in CFS patients.
Regulatory T Cell Assessment
Expression of FoxP3 Tregs was determined on
CD4
+CD25
+ cells. PBMC Cells were stained with mono-
clonal antibodies FITC-CD4 and APC-CD25 (BD Phar-
mingen, San Diego, CA) following which cells were
permeablised and stained with anti-FoxP3 and PE-Foxp3
respectively and analysed via flow cytometery [26].
Statistical Analysis
Statistical analyses were performed using SPSS soft-
ware version 16.0 (SPSS Inc, Chicago, USA). A sample
size of 59 participants per group was required to
obtain statistically significant results with an effect size
of 0.5 and a power of 85%. All data represented in this
study are reported as means plus orminus standard
error of the mean (± SEM). Comparative assessments
among participants (the CFS/ME and control subjects)
were performed using the analysis of variance test
(ANOVA) and independent sample t-test. All statisti-
cally significant results had p-values less than or equal
to 0.05.
Ethical Clearance and Participant Selection
Approval for this study was granted after review by the
Bond University Human Research Ethics Committee
(RO852A).
Results
Of the 168 participants recruited 95 met the CDC criteria
for CFS/ME and 50 qualified as healthy controls. Twenty-
three participants were rejected because they did not meet
the inclusion criteria for CFS/ME (Figure 1). 58.2% of
CFS/ME patients indicated that they experienced 6 or
more of the symptoms listed in the CDC criteria list and
21.4% experienced only 4 symptoms. The baseline charac-
teristics of the participants are illustrated in Table 1.
Lymphocyte Cytotoxic Activity
NK and CD8
+T (n = 71) cytotoxic activity measured as
the ability of NK and CD8
+T cells to effectively lyse
Table 1 Characteristics of participants in the study
Parameters Measured CFS/ME (n = 95) Controls (n = 50) p-values
Sex Female 70.5% Female 57.7%
Male 29.5% Male 42.3%
Mean Age 46.47 ± 11.7 41.9 ± 9.6 0.11
Height (cm) 167.47 ± 13.2 167.9 ± 8.9 0.16
Weight (lbs) 169.8 ± 140.7 159.8 ± 46.5 0.11
White Blood Cells 5.8 ± 1.4 6.3 ± 1.8 0.68
Lymphocyte (%) 38 ± 5.7 33.6 ± 7.9 0.03
Monocytes (%) 5.90 ± 1.4 5.6 ± 2.2 0.30
Granulocyte (%) 56.3 ± 7.1 60.8 ± 8.2 0.06
Lymphocyte (x10
3/μL) 2.3 ± 0.8 2.03 ± 0.6 0.24
Monocytes (x10
3/μL) 0.8 ± 4.2 0.34 ± 0.2 0.51
Granulocyte (x10
3/μL) 3.3 ± 1.0 3.87 ± 1.5 0.21
Red Blood Cells (x10
6/μL) 4.3 ± 0.5 4.56 ± 0.4 0.08
Heamoglobin (g/L) 131.6 ± 12.4 137.0 ± 11.7 0.15
Hematocrit (%) 43.8 ± 3.3 43.68 ± 13.0 0.89
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decreased (p < 0.05) among the CFS/ME patients com-
pared to the control subjects (Figure 2). Similarly gran-
zyme A expression was significantly decreased in both
the NK and CD8
+T cells in the CFS/ME population.
However, IFN-g and granzyme K were decreased only in
the NK cells of the CFS/ME group compared to the
healthy controls as shown in Figure 3A and 3B.
Altered NK Profiles in CFS/ME
For the purposes of this study NK phenotypes were clas-
sified into two, these are the CD56
brightCD16
- and
CD56
dimCD16
+NK cells. The number of NK cells
expressing CD56
brightCD16
- was significantly lower (p <
0.001) in the CFS/ME patients compared to the control
subjects (Figure 4C). However, CD56
dimCD16
+NK cells
remained unchanged across all groups (Figure 4C). The
raw data are presented in 4A and 4B.
Profile of CD4
+T cells Cytokines and VPACR2 in CFS/ME
After 72 hours of culture Th1 and Th2 cytokine secre-
tions were considerably different between groups, how-
ever, Th17 cytokine IL-17A remained unchanged.
However, IL-10, IFN-g and TNF-a production was signif-
i c a n t l ye l e v a t e di nt h eC F S / M Eg r o u pc o m p a r e dt ot h e
control group (Figure 5). Other cytokines IL-2 and IL-6
although increased in the CFS/ME population were not
statistically different between groups (Figure 5). IL-17A
was similarly not significantly different between the two
groups. FoxP3 secretion by Tregs was significantly higher
in the CFS/ME group compared to healthy participants
(Figure 6). Incidentally, Treg cell counts were also higher
in the CFS/ME group compared to the healthy popula-
tion (0.77 ± 0.10 vs. 0.24 ± 0.02). Lymphocyte expression
of VPACR2 was significantly higher in the CFS/ME
patients compared to the control group (Figure 7).
Discussion
This is the first study to show significantly higher levels
of VPACR2 receptors, CD4
+CD25
+Tregs and FoxP3
+Treg expression in CFS/ME patients compared to
healthy controls. In addition, CFS/ME patients had sig-
nificantly higher levels of anti-inflammatory cytokine IL-
10 and pro-inflammatory cytokines IFN-g and TNF-a.
This profile reflects significant and important immuno-
logical dysregulation that could explain some of the
clinical symptoms, for example the ongoing sickness
experience of CFS/ME patients.
This is the first study to provide a thorough investiga-
tion of the CD4
+Tc e l lp r o f i l ei nC F S / M Ep a t i e n t s
through the assessment of cytokine secretion and regu-
latory protein levels in particular VPACR2 receptors and
FoxP3 expression. Cytokines are soluble proteins with
either anti-inflammatory or pro-inflammatory effects.
Equivocal cytokine expression patterns in CFS/ME
patients have been reported without a definite identifica-
tion as to which cytokines may be specifically linked to
CFS/ME. Possible explanations for the inconsistencies in
cytokine distribution across studies are the heteroge-
neous nature of the disorder and differences in analyti-
cal methods used. However, newer and more sensitive
assays have been developed since the conflicting results
were reported [17]. It has been suggested that the
mechanism underlying CFS/ME may involve a shift in
cytokine production leading to either a predominant
Th1 or Th2 cytokine profile [27-29]. In the adaptive
immune system, CD4
+T cells subsets, Th1, Th2, Th17
and regulatory T cells (Tregs) are the main regulators of
cytokine secretion and the inflammatory immune
response. A bimodal Th1/Th2 response was observed in
the present study. A predominant Th1 and Th17
immune response has been linked to the development
or presence of an autoimmune disease whereas increases
in Th2 cytokines suggest the presence of other systemic
disorders [30,31]. Th1 cells secrete cytokines IFN-g and
IL-2 while Th2 cells secrete cytokines IL-4 and IL-10
[32] and Th17 secrete pro-inflammatory IL-17a, IL-17f
and IL-22 [33,34]. Recent data on cytokine networks in
CFS/ME show a predominant Th2/anti-inflammatory
profile in CFS/ME with a weakened Th1 profile [17].
This study supports the presence of a possible imbal-
ance in Th1/Th2 response in CFS/ME characterised by
a significant increase in IL-10 together with significant
increases in IFN-g and TNF-a.S u c hi n c r e a s e si nI L - 1 0
a r es u g g e s t i v eo fap e r s i s t e nt chronic infectious state
Figure 2 Reduced lytic function of cytotoxic cells in CFS/ME. In
vivo assessment of NK and CD8
+T cell lysis (cytotoxic activity) of
tumour cell lines K562 and P815 respectively in CFS/ME (black bars)
in comparison to controls (white bars). Lytic activity is represented
as percent (%) lysis on the y-axis. *Denotes statistical significant
results. Data presented as mean ± SEM.
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CD8
+T cell immune response [22]. Others have shown
that IL-10RA is differentially expressed in CFS/ME
patients, highlighting a potential compromise in IL-10
function or its receptor in CFS/ME patients [35,36].
Nonetheless, increased levels of IL-10, IFN-g and TNF-a
indicate the presence of fungal, bacterial or viral infec-
tion [37]. Incidentally in HIV elevation in IL-10, IFN-g
and TNF-a denote the presence of a chronic infection
and this correlated with viral load [38]. Similarly in CFS
Figure 3 mRNA Expression of cytotoxic molecules in NK and CD8
+T cells. Quantitative reverse transcriptase (RT)-PCR demonstrated the
relative expression of granzyme A, granzyme K, perforin and IFN-g in NK (A) and CD8
+T cells (B). In NK and CD8+T cells expression levels of
GZMA, GZMK and IFN-G were decreased in CFS/ME (black bars) compared to the controls (white bars). PRF1 was however increased in CFS
group. *Denotes statistical significant results (P ≤ 0.05). Data presented as mean ± SEM.
Figure 4 Distribution of NK phenotypes. NK phenotypes that were examined are denoted as either NK Bright (CD56
brightCD16
-)o rN KD i m
(CD56
dimCD16
+). (A). The box plots represent the raw data of NK Bright cells in the two groups. CFS/ME patients were more decreased in the
cell numbers for this particular NK phenotype. (B). However raw data of CD56
dimCD16
+NK cells were examined in the control and CFS/ME
groups, these were found to be similar. (C). Using the raw data from the flow cytometry results, total counts of NK cells were deduced. These
measurements are plotted using bar graphs, CD56
brightCD16
-NK cells are more reduced in the CFS/ME (black bars) group in comparison to the
controls (white bars). *Denotes statistical significant results (P ≤ 0.05). Data presented as mean ± SEM.
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increase in viral load and the occurrence of flu-like
symptoms. An increase in IL-10 also may contribute to
decreased cytotoxic activity observed in the NK and
CD8
+T cells [39,40]. The increase in pro-inflammatory
cytokines such as TNF-a, may also depict the presence
of an inflamed gut or irritable bowel syndrome in some
CFS/ME patients [41]. Inflammation in the gut can alter
the central nervous system [42,43] and affects various
physiological mechanisms including neuropeptides.
T h ec h a n g e si nb o t ht h eT h 1a n dT h 2r e s p o n s e sm a y
suggest changes in the function of VN receptor VPACR2
which is a key promoter and stimulator of anti-inflamma-
tory cytokines such as IL-10 [44]. It is important to note
that VNs, VIP and PACAP have never been assessed in
CFS/ME previously. These important neuropeptides
increase IL-10 gene expression via the cAMP response
element DNA binding complex pathway, therefore
changes in VNs such as elevations in VPACR2 may sug-
gest an increase in IL-10 [45]. Further, an increase in
TNF-a and IFN-g suggests an inability of the heightened
VPACR2 to suppress TNF-a and IFN-g secretion as
these neuropeptides are noted to suppress pro-inflamma-
tory cytokines while favouring anti-inflammatory
Figure 5 Examination of the expression levels of CD4+T cell
Related Cytokiness in CFS/ME following mitogenic stimulation.
CD4
+T cells, Th1, Th2 and Th17 cytokine levels in CFS/ME (black
bars) and control participants (white bars) measured after mitogenic
stimulation with PHA. The concentrations of cytokines were
measured in pg/mL. Both anti-inflammatory (IL-10) and pro-
inflammatory (IFN-g, TNF-a) cytokines were increased in the CFS/ME
group following mitogenic stimulation. *Statistically significant
results at p < 0.05. Data presented as mean ± SEM.
Figure 6 FoxP3 expression and CD4+CD25+T cells in CFS/ME.
The percentage of CD4+T cells expressing CD4+CD25+FoxP3+
markers are represented in the bar graph. Tregs of interest in this
study were those positive for FoxP3 and CD4+CD25+ in CFS/ME
(black bars) and control (white bars) participants. *Represent
statistically significant results at p < 0.05. Data presented as mean ±
SEM.
Figure 7 VPAC2R immune cells in CFS/ME. VPAC2R expression
on CD4
+T cells was assessed in CFS/ME (black bars) and controls
(white bars). The data presented here are based on percentage of
cells positive for CD4 and VPACR2. *Represent statistically significant
results at p < 0.05. Data presented as mean ± SEM.
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VPACR2 potentially suggest changes in cAMP associated
with the inflammatory immune response in CFS/ME.
Although our study did not assess the levels of cAMP
present in CFS/ME patients, VIP binding to its receptor,
in this case VPACR2, is known to stimulate the presence
of FoxP3
+ which assists in regulating the T cell response.
Thus it is consistent that heightened levels of VPACR2
will translate into heightened FoxP3 expression. FoxP3
+
Tregs also secrete IL-10 which maintains the expression
of FoxP3 in Tregs [47]. The increased expression of IL-
10 and the relatively higher expression of FoxP3 together
with significant increases in CD4
+CD25
+Tregs suppres-
sive activity suggest a requirement to counter a signifi-
cant pro-inflammatory response in these patients. While
levels of viral antigens were not measured in this study,
these observations may suggest a plausible prevalence in
viral antigens, adjuvants or autoantibodies in the periph-
eral circulation of CFS/ME patients [48,49].
NK cytotoxic activity in CFS/ME has received much
attention while only one study has examined CD8
+Tc e l l
cytotoxic activity. Most studies found significant decreases
in NK activity and one study found decreased CD8
+T cell
cytotoxic activity in a CFS/ME population compared with
a control group. These findings are confirmed in our
study. In a previous study [13] as well as this study in a
larger population we have found that NK cytotoxic activity
and CD56
bright NK phenotypes are decreased in CFS/ME
patients. These atypical cytotoxic responses may be linked
to compromised granule-mediated cell death pathways
involving apoptotic mediators, perforin and granzymes.
Perforin forms pore-like structures to facilitate the entry
of granzymes into the target cell [50], and granzymes acti-
vate several apoptosis pathways that ensure effective killing
of the target cell [51]. Perforin and granzymes have been
shown to be decreased in both NK and CD8
+T cells in
CFS/ME [16,52]. In contrast both granzyme A and gran-
zyme K were significantly reduced while perforin levels
were elevated in both the NK and CD8
+T cells of CFS/ME
patients. Reduced cytotoxic activity may therefore be an
important component of the immune dysregulation seen
in CFS/ME.
Conclusions
These results illustrate a severely compromised immu-
nomodulation mechanism in CFS/ME where attempts
to regulate or restore immune homeostasis appear to be
impaired. These findings suggest that certain immunolo-
gical biomarkers as demonstrated in this study may be
unique to CFS/ME. To date no routinely available clini-
cal immunological markers have been identified that
characterise CFS/ME, resulting in poor recognition and
management of patients. The immunological abnormal-
ities identified in our study can potentially fill this void
as potential biomarkers and assist clinicians and patients
in diagnosis and management of this severely debilitat-
ing condition. These biomarkers may include NK phe-
notypes, NK activity, CD8
+T cell activity, IL-10, IFN-g
TNFa, FoxP3 and VPACR2. These markers that seem
to be unique to CFS/ME patients could assist in identi-
fying them as a distinct population, enabling more
appropriate clinical management and better targeted
scientific investigations into the underlying pathome-
chanisms of the disease.
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